 Lenalidomide is a 4-amino-glutaryl derivative of thalidomide and belongs to a new generation of immunomodulatory agents for the treatment of patients with myelodysplastic syndrome<disease><symptom> and multiple myeloma. The aim of this study is to evaluate the bioequivalence and safety of a capsule containing 25 mg of a test formulation of lenalidomide and a 25 mg Revlimid This was a single-center , randomized , open-label , single-dose , two-period , crossover pharmacokinetic study. Forty-eight healthy , adult Chinese males were administered a test lenalidomide or Revlimid Twenty-four subjects in the fasting group and 23 in the postprandial group completed the clinical trial. Subjects administered test lenalidomide and Revlimid According to the criteria for bioequivalence , the test formulation of lenalidomide and Revlimid